Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Gilteritinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 known ✓ | P36888 | 14/20 | 1.00 |
| ▸ | AXL known ✓ | P30530 | 2/20 | 1.00 |
| ▸ | EML4 | Q9HC35 | 13/20 | 1.00 |
| ▸ | ALK | Q9UM73 | 13/20 | 1.00 |
| ▸ | RET | P07949 | 12/20 | 1.00 |
| ▸ | ROS1 | P08922 | 12/20 | 1.00 |
| ▸ | ETV6 | P41212 | 2/20 | 1.00 |
| ▸ | BMPR1B | O00238 | 1/20 | 1.00 |
| ▸ | PLK4 | O00444 | 1/20 | 1.00 |
| ▸ | CIT | O14578 | 1/20 | 1.00 |
| ▸ | AURKA | O14965 | 1/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | EPHB6 | O15197 | 1/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 1/20 | 1.00 |
| ▸ | BUB1 | O43683 | 1/20 | 1.00 |
| ▸ | SNRNP200 | O75643 | 1/20 | 1.00 |
| ▸ | STK16 | O75716 | 1/20 | 1.00 |
| ▸ | STK10 | O94804 | 1/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 1/20 | 1.00 |
| ▸ | LATS1 | O95835 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gilteritinib SCHEMBL29432551 | 1.00 | FLT3 (1.00) | FLT3EML4ALKRETROS1 | |
| Gilteritinib SCHEMBL282229 | 1.00 | FLT3 (1.00) | FLT3EML4ALKRETROS1 | |
| SCHEMBL328303 | 0.97 | FLT3 (0.94) | FLT3EML4ALKRETROS1 | |
| Gilteritinib SCHEMBL21819929 | 0.96 | FLT3 (1.00) | FLT3EML4ALKRETROS1 | |
| Gilteritinib SCHEMBL29357951 | 0.96 | FLT3 (1.00) | FLT3EML4ALKRETROS1 | |
| SCHEMBL29157675 | 0.96 | FLT3 (0.92) | FLT3EML4ALKRETROS1 | |
| Gilteritinib SCHEMBL22684910 | 0.95 | FLT3 (0.91) | FLT3EML4ALKRETROS1 | |
| Gilteritinib SCHEMBL22684912 | 0.95 | FLT3 (0.91) | FLT3EML4ALKRETROS1 | |
| SCHEMBL22652336 | 0.94 | FLT3 (0.89) | FLT3EML4ALKRETROS1 | |
| SCHEMBL21455071 | 0.94 | FLT3 (0.89) | FLT3EML4ALKRETROS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2608 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122075716-A | Medicine for treating tumor by combining recombinant oncolytic virus and small-molecule anticancer medicine | — | 2026-05-26 | — | — | CN | claimed |
| WO-2026105121-A1 | ANTICANCER FORMULATIONS AND USES THEREOF | INTRAGEL THERAPEUTICS LTD. (IL) | 2026-05-21 | — | — | WO | claimed |
| EP-4743074-A1 | METHODS OF TREATING HEMATOLOGIC CANCER | Foghorn Therapeutics Inc. (US) | 2026-05-20 | — | — | EP | claimed |
| EP-4743086-A2 | TREATING MYELOID DISORDERS | Mayo Foundation for Medical Education and Research (US) | 2026-05-20 | — | — | EP | claimed |
| US-20260130856-A1 | LIPOSOME COMPOSITIONS FOR DELIVERY OF COMPOUNDS AND METHODS THEREOF | NANOTECH PHARMA INC (US) | 2026-05-14 | — | — | US | claimed |
| EP-4741395-A1 | NOVEL COMPOUND SENSITIVE TO NITROGEN MONOXIDE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Omniamed Co. Ltd (KR) | 2026-05-13 | — | — | EP | claimed |
| WO-2026090174-A1 | COMPOSITIONS FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS AND METHODS FOR THE SYNTHESIS AND USE THEREOF | BRYET US, INC. (US) | 2026-04-30 | — | — | WO | claimed |
| WO-2026087815-A1 | TREATMENT OF DISEASES CAUSED BY NETOSIS OR DISEASES ASSOCIATED WITH NEUTROPHIL EXTRACELLULAR TRAPS (NET) | FUNDACIÓN PARA LA FORMACIÓN E INVESTIGACIÓN SANITARIAS DE LA REGIÓN DE MURCIA (ES) | 2026-04-30 | — | — | WO | claimed |
| EP-4731213-A2 | COMBINATION THERAPY INVOLVING MACROCYCLIC INDAZOLE COMPOUNDS | Blossomhill Therapeutics, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| EP-4731792-A2 | COMPOSITIONS COMPRISING ANTINEOPLASTONS AND METHODS OF TREATING LUNG CANCER | Burzynski, Stanislaw R. (US) | 2026-04-29 | — | — | EP | claimed |
| WO-2022068933-A1 | COMPOUNDS AND METHODS OF TREATING DISEASES | CULLGEN (SHANGHAI) , INC. (CN) | 2022-04-07 | — | — | WO | claimed |
| WO-2022065618-A1 | METAL (HYDR)OXIDE COMPOSITE COMPRISING POORLY SOLUBLE DRUG, METHOD FOR MANUFACTURING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 주식회사 위바이오트리 | 2022-03-31 | — | — | WO | claimed |
| EP-3373932-B1 | CRYSTALLINE FORM OF A SUBSTITUTED QUINOLINE COMPOUND AND PHARMACEUTICAL COMPOSITIONS THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2022-03-30 | — | — | EP | claimed |
| US-11285154-B2 | Methods and compositions for treating cancer | UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2022-03-29 | — | — | US | claimed |
| US-20220062242-A1 | Methods and compositions for inhibiting mutant EGFR signaling | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2022-03-03 | — | — | US | claimed |
| WO-2022031476-A2 | METHODS AND COMPOSITIONS FOR PROTEASE REPORTER ASSAYS AND MODULATORS | 712 NORTH, INC. (US) | 2022-02-10 | — | — | WO | claimed |
| WO-2022029334-A1 | COMBINATION THERAPIES FOR TREATING CORONAVIRUS INFECTION | GBIOTECH S.À.R.L. (CH) | 2022-02-10 | — | — | WO | claimed |
| WO-2022029782-A1 | LONG ACTING ANTICANCER COMPOSITIONS | INTRAGEL THERAPEUTICS LTD. (IL) | 2022-02-10 | — | — | WO | claimed |
| US-20220040324-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND KINASE INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-02-10 | — | — | US | claimed |
| EP-3942045-A1 | A DBAIT MOLECULE IN COMBINATION WITH KINASE INHIBITOR FOR THE TREATMENT OF CANCER | ONXEO (FR) | 2022-01-26 | — | — | EP | claimed |